Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
- Sector(s): Healthcare
- Industry: Biotechnology
- Formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016
- Incorporated in 2013
- HQ in Los Angeles, California.
- https://kairospharma.com
Kairos Pharma (NYSEMKT:KAPA) priced on Monday its initial public offering of 1.5M shares of common stock at a public offering price of $4 per share. The gross proceeds from the offering are expected to be $6.2M.
No comments:
Post a Comment